Navigation Links
EDAP TMS S.A. Announces $20 Million Placement to Fund US Clinical Studies

LYON, France, Oct. 30 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP) the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announces that it has entered into a securities purchase agreement with selected United States based qualified institutional buyers ("Investors") pursuant to which the Investors will purchase US $20 million in Unsecured Convertible Debentures convertible into EDAP's ordinary shares which will be delivered in the form of American Depository Receipts ("ADR") at a conversion price of US $6.57.

Proceeds will be used to fund EDAP's already ongoing US Phase II/III clinical study of the Ablatherm-HIFU system in the treatment of localized prostate cancer. The study is treating patients at leading US clinical locations nationwide, with additional centers slated to join. HIFU has been approved for use in the European Union and has been used in over 13,000 cases at centers worldwide; current peer-reviewed clinical studies documenting efficacy and side effects using Ablatherm-HIFU over the past 10 years are available from the company or online at and .

The debentures will mature five years from the date of closing bearing 9% interest. EDAP may, provided certain conditions are met, elect to pay all or a portion of interest on the debentures in the form of ADRs. The Investors will also receive warrants to purchase an additional 1,680,000 ADRs at an exercise price of US $6.87, which will expire six years from closing. As part of the transaction, the company has agreed to file a registration statement on Form F-3 with the Securities and Exchange Commission within 30 days following the closing for the purpose of registering for resale the American Depository Shares evidencing the ordinary shares deliverable upon conversion of the debentures, exercise of the warrants and payable in interest.

The securities issued in connection with the private placement referenced herein have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be, absent any exemption therefrom, any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and

commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

To sign up for alerts please visit:

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A. Magnolia Investor Relations

Blandine Confort Matt Kreps

+33 4 78 26 40 46 469 362 5960

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
(Date:12/1/2015)... FL (PRWEB) , ... December 01, 2015 , ... ... announces the Multi Jar, a container patent that allows for easier packing and organizing ... the US is worth $90 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:12/1/2015)... ... ... Royal River Natural Foods — a locally-owned, independent natural health store in ... nutritional supplement creatine, along with resistance training for a year, had more new bone ... report is part of the December 2015 issue of Natural Insights for Well Being®, ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from ... care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... payments per claim with more than seven days of lost time continued to be ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 ... "Medium Molecular Weight Polyisobutylene Market for ... Applications - Global Industry Analysis, Size, Share, ... report to their offering. --> ... of the "Medium Molecular Weight Polyisobutylene ...
(Date:12/1/2015)... /PRNewswire/ -- Royal Philips  (NYSE: PHG, ... imaging software that produces high-contrast images for all anatomies ... grid, at the 2015 Radiological Society of North ... Philips, first digital imaging solution providing grid-like contrast improvement ... workflow and supports "first-time-right imaging" by decreasing the need ...
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
Breaking Medicine Technology: